FDA Approves Xeglyze™ for the topical treatment of head lice infestation Media ReleaseCarolyn MillerAugust 3, 2020Hatchtech, Paul Kelly
Hatchtech inks $279m head lice deal as VC market comes to life Sydney Morning HeraldCarolyn MillerSeptember 14, 2015Hatchtech, OneVentures
Hatchtech Pty Ltd to explore strategic alternatives for commercialization of Xeglyze™ lotion in the U.S. Media ReleaseCarolyn MillerMarch 26, 2015Hatchtech
Hatchtech announces successful results from Phase 2 ovicidal study Media ReleaseCarolyn MillerOctober 21, 2014Hatchtech, Paul Kelly
Australia’s Hatchtech ‘itching’ to partner at J.P. Morgan BioWorldCarolyn MillerJanuary 27, 2014Hatchtech
No nit picking: Head lice group Hatchtech gets green light to trials AFRCarolyn MillerFebruary 1, 2018Hatchtech, Paul Kelly
Hatchtech gets new VC backing for lice treatment trial The AustralianCarolyn MillerNovember 1, 2013Hatchtech, Paul Kelly
Hatchtech hardly a head-scratcher for investors LabOnlineCarolyn MillerNovember 1, 2013Hatchtech, Paul Kelly
Hatchtech completes $12.5M capital raise, secures funds for phase III trial and NDA submissions, and announces board changes Media ReleaseCarolyn MillerOctober 31, 2013Hatchtech, Paul Kelly
Hatchtech publish data on Head Lice treatment safety study and mechanism of action Media ReleaseCarolyn MillerNovember 27, 2012Hatchtech, Paul Kelly
Novel Pediculicide Clears Most Head Lice With 1 Application MedscapeCarolyn MillerOctober 25, 2012Hatchtech, Paul Kelly
Hatchtech announce successful End-of-Phase 2 for head lice product DeOvo™ Media ReleaseCarolyn MillerSeptember 4, 2012Hatchtech, Paul Kelly
Hatchtech raises $6.3m for DeOvo™ Head Lice Phase 2b Clinical Trial Media ReleaseCarolyn MillerOctober 26, 2010Hatchtech, Paul Kelly
Hatchtech wins prize for best Victorian technology commercialisation from all industries AwardsCarolyn MillerJune 21, 2006Hatchtech, Paul Kelly
Hatchtech wins Commercialisation Expo 2006 Prize for Best Australian Life Sciences Company AwardsCarolyn MillerJune 21, 2006Hatchtech, Paul Kelly
